

For Immediate Release
Alembic Pharmaceuticals Limited
Consolidated Results for quarter ended 30.09.2013

Revenues up 20% at Rs 488 crores against Rs. 408 crores in PY
PBT up 52% at Rs 80.49 crores against Rs. 52.98 crores in PY

Editors Synopsis

- **Net sales up 20% at Rs 488 crores for the quarter against Rs. 408 crores in corresponding quarter last year**
- **Profit before tax up 52% at 80.49 crores against Rs. 52.98 crores in corresponding quarter last year**
- **Net profit after tax up 45% for the quarter at Rs. 61.64 crores vis-à-vis Rs. 42.49 in corresponding quarter last year**
- **EBITDA at 19.06% at Rs. 92.71 crores vs 15.91% at Rs. 64.70 crores in corresponding quarter last year**
- **International Generic Formulations sales up 123% for the quarter at Rs. 114 crores against Rs. 51 crores in corresponding quarter last year**
- **Domestic Branded formulations sales up 10% for the quarter at Rs. 241 crores against Rs. 220 crores in corresponding quarter last year**
- **Net sales up 18% for H1 at Rs. 916 crores against Rs. 776 crores for corresponding H1 last year**
- **PBT up 55% for H1 at Rs. 141 crores against Rs. 91 crores for corresponding H1 last year**

Vadodara, 25th October, 2013

Alembic Pharmaceuticals Limited reported a 20% increase in revenues to Rs 487.67 crores for the quarter ended 30th September 2013, compared to Rs 407.53 crores in the corresponding quarter last year.

The Company posted 52% growth in profit before tax at Rs. 80.49 crores for the quarter ended 30th September 2012 against Rs 52.98 crores posted in corresponding quarter last fiscal.

The net profit grew by 45% at Rs. 61.64 crores for the quarter ended 30th September 2013 against Rs. 42.49 crores in corresponding quarter last fiscal.

EBIDTA margins for quarter ended 30th September 13 up at 19% to Rs. 92.71 crores from 15.9% for corresponding quarter last year.

The company also reported 18% increase in revenue for first half of operations to Rs. 916.45 crores against Rs. 775.59 crores corresponding first half last year.

The company also posted 55% growth in profit before tax at Rs. 140.99 crores for first half against Rs. 91.08 crores for corresponding first half last year. The Company also reported 48% growth in net profit for first half at Rs. 108.28 crores against Rs. 73.33 crores in corresponding first half last year.

Domestic Formulations Business

The Branded Domestic formulations business posted sales of Rs. 241.01 crores against Rs. 219.86 crores with a 10% growth over the corresponding quarter of the previous year.

As per ORG IMS, Alembic has maintained market share of 1.78%.

Speciality and Acute segments grew by 24% and Nil respectively in current year (MAT-Sept 13) versus Industry growth rate of 11% and 3% respectively.

International Generics

International Generic Formulation posted growth of 123% and posted sales of Rs. 113.67 crores against Rs. 51.01 crores over the corresponding quarter last year.

During the quarter 2 ANDA application were filed taking cumulative ANDA filings of the Company to 59. 1 ANDA approval was received during the quarter. Cumulative ANDA approvals now stands at 30 (including 4 tentative approvals).

Summary of total revenue is as under:

(Rs. in Lacs)

Particulars	Q2 FY14	Q2 FY13	% Change	H1 FY14	H1 FY13	% Change
Formulation						
Domestic	27485	25387	8%	49607	45111	10%
International Branded	1436	868	65%	2657	1623	64%
International Generics	11367	5101	123%	19914	9706	105%
API	7820	9095	(-)14%	18517	20490	(-)10%
Export Incentives	659	302	-	950	629	-
Total	48767	40753	20%	91645	77559	18%

The Profit break-up for the quarter is as under:

(Rs. in Lacs)

Particulars	Q2 FY14	Q2 FY13	% Change	H1 FY14	H1 FY13	% Change
Operating Income	9271	6470	43%	16419	11699	40%
Profit Before Tax	8049	5298	52%	14099	9108	55%
Net Profit after Tax	6164	4249	45%	10828	7333	48%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 3800 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Alembic Pharmaceuticals Limited

Mitanshu Shah

Phone: +91 265 – 3007630

Email: mitanshu.shah@alembic.co.in

Ajay Desai

Phone: +91 022 – 306 11681

Email: ajay.desai@alembic.co.in